De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Indivior Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Indivior is gedaald met een gemiddeld jaarlijks percentage van -23.2%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks daalde met 2.4%. De inkomsten zijn groeide met een gemiddeld percentage van 9.1% per jaar.

Belangrijke informatie

-23.2%

Groei van de winst

-23.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	14.1%
Inkomstengroei	9.1%
Rendement op eigen vermogen	n/a
Nettomarge	-12.3%
Volgende winstupdate	24 Oct 2024

Recente prestatie-updates uit het verleden

Recent updates

Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump

Sep 24

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Aug 09

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

May 29

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

May 03

Opbrengsten en kosten

Hoe Indivior geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

LSE:INDV Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	1,147	-141	750	101
31 Mar 24	1,124	5	571	107
31 Dec 23	1,093	2	543	106
30 Sep 23	1,042	-235	526	106
30 Jun 23	1,002	-59	488	108
31 Mar 23	947	-50	469	91
31 Dec 22	901	-53	461	72
30 Sep 22	882	166	460	62
30 Jun 22	838	152	460	53
31 Mar 22	818	166	446	51
31 Dec 21	791	205	425	52
30 Sep 21	753	156	402	47
30 Jun 21	725	139	384	43
31 Mar 21	674	95	391	39
31 Dec 20	647	-148	427	40
30 Sep 20	595	-190	428	43
30 Jun 20	634	-152	439	47
31 Mar 20	700	-95	427	51
31 Dec 19	785	134	390	53
30 Sep 19	889	213	386	53
30 Jun 19	935	254	404	58
31 Mar 19	988	248	449	63
31 Dec 18	1,005	275	478	67
30 Sep 18	1,033	106	722	72
30 Jun 18	1,064	67	760	79
31 Mar 18	1,083	71	730	80
31 Dec 17	1,093	58	707	89
30 Sep 17	1,087	281	482	99
30 Jun 17	1,080	81	434	104
31 Mar 17	1,065	65	444	113
31 Dec 16	1,058	35	456	119
30 Sep 16	1,047	-6	443	128
30 Jun 16	1,028	191	440	137
31 Mar 16	1,021	201	423	143
31 Dec 15	1,014	228	408	132
30 Sep 15	1,037	268	388	143
30 Jun 15	1,058	314	368	131
31 Mar 15	1,085	361	332	119
31 Dec 14	1,115	403	343	115
30 Sep 14	1,147	443	325	99
31 Dec 13	1,216	489	341	76

Kwaliteitswinsten: INDV is momenteel verliesgevend.

Groeiende winstmarge: INDV is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: INDV is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 23.2% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van INDV over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: INDV is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 4.5% ).

Rendement op eigen vermogen

Hoge ROE: De schulden van INDV zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.

Indivior Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022)

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022)

Recent updates

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump

Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Consensus EPS estimates increase by 44%

Consensus EPS estimates fall by 37%

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

CEO & Executive Director recently sold UK£1.5m worth of stock

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Chief Human Resources Officer recently sold UK£1.8m worth of stock

The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More

Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022)

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

New major risk - Financial position

Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022)

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022)

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

Chief Manufacturing & Supply Officer recently sold UK£1.7m worth of stock

Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings: Revenues in line with analyst expectations

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly

High number of new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year

Indivior plc Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021)

Indivior (LON:INDV) Seems To Use Debt Quite Sensibly

Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022